Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
REGULATORY
Japan Approves Padcev, Entresto’s Hypertension Use, Lilly’s RET Inhibitor and More
Japan’s Ministry of Health, Labor and Welfare (MHLW) on September 27 approved a batch of new medicines and additional indications including Astellas Pharma’s antibody-drug conjugate (ADC) Padcev (enfortumab vedotin) and the label expansion of Novartis’ Entresto (sacubitril valsartan sodium hydrate)…
To read the full story
Related Article
- Lilly’s RET Inhibitor, Pfizer’s Oral JAK Drug Make Japan Debut
December 14, 2021
- November Listing OK’ed for Cibinqo, Retevmo, Padcev and More
November 17, 2021
- Astellas’ Padcev, Pfizer’s JAK Inhibitor, AZ’s Lupus Drug Clear PAFSC Panel
September 7, 2021
- Entresto Clears MHLW Panel with Strings Attached, It’s Not a 1st Choice Drug
September 6, 2021
- MHLW Panel Shelves Decision on Entresto’s Hypertension Use, Clears Otsuka’s Eczema Med and More
August 31, 2021
- Lilly’s Selpercatinib Clears Key Panel, in Line for September Approval
August 2, 2021
REGULATORY
- Kisunla Price Cut Set at 3.93% under Japan’s CEA Scheme
November 6, 2026
- Japan Nudged to Probe Wide Gaps in Biosimilar Uptake
November 6, 2026
- Japan Eyes Multi-Year Investment Support for Wholesalers in FY2027 Budget
November 6, 2026
- Japan Poised to Broker Generic Firms’ Product Consolidation Talks
November 6, 2026
- Japan Issues Guidance on AI Model Use in Drug Manufacturing, Quality Control
November 6, 2026
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…